Xebra Brands Stock Price, News & Analysis

Xebra Brands (XBRA:CSE)(XBRAF:OTCQB) has completed its previously announced shares for debt transaction, settling $448,146 in accrued liabilities through the issuance of 8,962,917 common shares at $0.05 per share. The settlement includes payments to officers, directors, consultants, and service providers.

Of the total shares, 3,730,917 were issued to company insiders, constituting a related party transaction under MI 61-101. Additionally, 7,476,000 settlement shares are subject to a four-month hold period.

The company also announced plans for a non-brokered private placement offering of up to 3,000,000 units at $0.05 per unit, aiming to raise up to $150,000. Each unit includes one common share and half a warrant, with each full warrant exercisable at $0.10 for 24 months.

Xebra Brands (CSE:XBRA) has announced a non-brokered private placement offering of up to 3,000,000 units at $0.05 per unit, aiming to raise gross proceeds of up to $150,000. Each unit consists of one common share and one-half warrant, with each full warrant exercisable at $0.10 for 24 months.

Additionally, the company plans to settle $450,000 in accrued liabilities through the issuance of up to 9,000,000 common shares at $0.05 per share to officers, directors, consultants, and service providers. The closing of both transactions is expected around January 30, 2025.

The proceeds will be used for general corporate and working capital purposes. Company insiders are expected to participate in both transactions, which qualify as related party transactions under MI 61-101, though exemptions from formal valuation and minority shareholder approval requirements are expected to apply.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) has announced an extension of the expiry date for 13,311,731 outstanding warrants. The 2023 Warrants, with an exercise price of $0.10, were initially set to expire on September 6, 2024, then extended to December 31, 2024, and are now being further extended to June 30, 2025, subject to Canadian Securities Exchange approval.

According to Interim CEO Rodrigo Gallardo, several warrant holders have shown interest in exercising their warrants, and this extension will provide time for the process. The funds from these warrants are intended to provide additional capital to support growth and strengthen the company's first-mover advantage in Mexico.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF) has signed its first distribution agreement with ICAN Pharmacies FADERMEX for ELEMENTS-branded products across seven Mexican pharmacy locations. The products, manufactured at Restorative Botanicals, will be available once final importation permits are granted. This follows a February 2024 agreement where ICAN would supply CBD isolate to Xebra's subsidiary, Desart MX S.A. de C.V., for CBD product production in Mexico. ICAN FADERMEX Pharmacies is operated by ICAN Green, a division of ICAN Investing Group , focusing on cannabis-based medications in Latin America.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0), a cannabis company, has announced the extension of the expiry date for 13,311,731 outstanding warrants. These 2023 Warrants, originally issued on March 6, 2023, with an initial exercise price of CAD$0.10, were set to expire on September 6, 2024. The company has proposed to extend the expiration date to December 31, 2024. All other terms and conditions of the warrants remain unchanged.

Interim-CEO Rodrigo Gallardo stated that this extension will provide time for close shareholders who have expressed interest in exercising warrants, potentially providing necessary capital for the company to grow and execute its first-mover advantage in Mexico. The Canadian Securities Exchange (CSE) has approved the warrant extension.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAD)(FSE:9YC0), a cannabis company, has closed its previously announced shares for debt transaction. The company settled an aggregate debt of $182,854.65 through the issuance of 2,031,716 common shares at a deemed price of $0.09 per share. This debt settlement includes accrued liabilities for fees and expenses owed to certain officers, directors, and consultants.

The transaction aims to preserve funds for operations and growth opportunities. 888,383 shares are subject to a four-month hold period. Notably, 703,333 shares were issued to company insiders, constituting a 'related party transaction' under MI 61-101, with Xebra relying on exemptions from formal valuation and minority shareholder approval requirements.

Xebra Brands, a cannabis industry leader, has engaged MPC Co, led by Melise Panetta, to spearhead its expansion into Mexico and the US. Panetta brings over 20 years of CPG experience and nearly a decade in the cannabis industry. Her expertise includes senior roles at PepsiCo, SC Johnson, and General Mills, as well as consulting for global cannabis brands.

Panetta will focus on developing strategic relationships with major Mexican retailers like Costco, GNC, and OXXO, which already carry CBD products. She will also play a key role in creating marketing, sales, and consumer strategies for the Elements Brand and contribute to corporate initiatives to strengthen Xebra's position in the Mexican market.

Xebra Brands has successfully completed the first manufacturing run of its Elements line, signifying a major step in its commercialization efforts in Mexico. This milestone follows the regulatory approval by COFEPRIS for Xebra's subsidiary, Elements Bioscience, to import, launch, and sell Elements Full Spectrum CBD Tinctures. These products are set to hit wellness stores, pharmacies, and retail channels amid growing demand for CBD-based products. The Mexican cannabis market is forecasted to reach $3.2B by 2026, with $210M from CBD sales. Xebra stands out as the only company legally allowed to operate in the Mexican cannabis sector, highlighting its pioneering role and commitment to quality and safety.

Xebra Brands has announced an expansion of its strategic partnership with ICAN Ventures, focusing on enhancing the formulation of its Elements brand CBD products in Mexico. This collaboration leverages ICAN's advanced laboratories and specialized team to develop precise, bioavailable, and safe CBD formulations. The aim is to produce tailored products for various consumer segments, including athletes, those seeking relaxation or skincare solutions, and pet products.

The partnership marks a milestone in Xebra’s plans to dominate the Mexican cannabis market, utilizing ICAN's expertise to ensure high-quality, effective products. Additionally, Xebra plans to settle $220,000 in debt through the issuance of 2,444,444 common shares at $0.09 per share, expected to conclude by July 8, 2024, pending approval from the Canadian Securities Exchange.